Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1583 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Nanyang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442 was administered intramuscularly or intravenously (300 or 600 mg). End points included safety, tolerability, pharmacokinetics, antidrug antibodies, and SARS‐CoV‐2–neutralizing antibody titers. Sixty participants were randomized and dosed (AZD7442, n = 49; placebo, n = 11). Adverse events occurred in 45 (91.8%) and 9 (81.8%) participants, serious adverse events occurred in 2 (4.1%) and 0 (0%) participants in AZD7442 and placebo groups, respectively, and there were no deaths. Tixagevimab and cilgavimab had mean half‐lives of 82.4‐88.1 (range across dosing groups) and 79.0‐83.7 days, respectively. In participants who received AZD7442, 3 (6.1%) were treatment‐emergent antidrug antibody positive. SARS‐CoV‐2–neutralizing antibody titers were more than 4‐fold higher than baseline levels by Day 8, then decreased through Day 361 following AZD7442 administration. AZD7442 was well tolerated in healthy Chinese adults, demonstrating predictable pharmacokinetics and an extended half‐life consistent with previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Clinical Trial Institution, Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
- Shanghai Sci-Tech Inno Center for Infection & Immunity, Shanghai, China.
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China.
Zitieren
APA
Li, N., Zhang, J., Zhang, W., Xu, Z., Yao, X., He, A., Liu, S., Ge, X., Liu, J., Li, Y., Chen, C. C., & Zhang, H. (2025). Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1583
Vancouver
Li N, Zhang J, Zhang W, Xu Z, Yao X, He A, et al. Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1583
BibTeX
@article{Li2025,
author = {Li, Nanyang and Zhang, Jing and Zhang, Wenhong and Xu, Zhongyuan and Yao, Xiangcao and He, Anqi and Liu, Shuyuan and Ge, Xiaoyun and Liu, Jinxi and Li, Yunfei and Chen, Cecil Chi-Keung and Zhang, Huixia},
title = {Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1583}
}
EUVIMED